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Background. Abatacept (CTLA4-Ig) is an approved biological therapy for the treatment of 
rheumatoid arthritis (RA). Similar to other biological agents, most patients (60%) respond 
significantly to this therapy. To date, however, the biological mechanisms underlying the lack of 
efficacy for this drug are unknown. 
 
Objetives. The objectives of the present study were to characterize the biological processes 
underlying the lack of efficacy of abatacept and to evaluate the blood transcriptome as a valid 
source for drug response prediction. 
 
Methods:. A total of n=57 patients diagnosed with RA were recruited for this study from 16 
rheumatology departments in Spain. All patients were >18 years old and, had >6 months of disease 
evolution. The primary clinical response to abatacept was defined at week 12 using the EULAR 
criteria. Good and moderate responders were aggregated into a single response group, and 
compared to the no response group of patients. Blood RNA was collected from all patients at 
baseline. From a subgroup of patients (n=31), blood RNA was also obtained at weeks 12, 24 and 
48 of treatment with abatacept. Gene expression levels were determined using paired-end RNA-
seq (Illumina). Differential gene expression, association to biological processes, longitudinal 
association analysis and building of the multigenic predictor were performed using the R software 
and the specialized Bioconductor libraries. The the prediction accuracy was evaluated using the 
ROC AUC. 
 
Results. From the 57 patients treated with abatacept, n=10 (17.5%) were good EULAR 
responders, n=24 (42%) moderate EULAR responders and n=23 (40.5%) non-responders at week 
12 of therapy. Biological process analysis identified two significantly distinct biological profiles 
between responders and non-responders. In responders, we found an association to pathways 
associated with the effector phase of T cells (e.g. interleukin-15 and 2 signalling, P < 0.05). Non-
responder patients showed instead a strong association to biological processes associated with 
antigen presentation and activation of T cells (P < 0.005). Using the baseline gene expression 
profiles, we built a multigenic predictor of response to abatacept with an AUC = 75%. In the 
longitudinal cohort, patients were stratified based on reaching an inactive state (i.e. DAS28 < 3.2). 
Using this endpoint measure, the longitudinal analysis of the 4 time points corroborated the 
association of response with antigen presentation (P < 0.01). 
 
Conclusion. The analysis of blood RNA profiles of RA patients has enabled the identification 
of specific biological processes associated with the lack of response to abatacept. Also, we 
demonstrate that blood expression profiles can be predictive of the response to the drug at week 12 
of therapy. 
